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Abstract. A simple reversed phase HPLC method with UV detection has been successfully 
developed and validated for determination of moxifloxacin in human plasma. The sample 
pretreatment involves only single-step protein precipitation with trichloroacetic acid. 
Moxifloxacin was measured in plasma using a validated HPLC method with UV detector at 295 
nm, C18 column (25 cm × 4.5 mm, 5 µm), a mixture of phosphate buffer pH 4.0 and acetonitrile 
(30:70, v/v) as mobile phase at a flow rate of 0.8 mL/min. Retention time of moxifloxacin was 
found to be 7.4 min. The mean recovery for the drug was obtained 97.30 %. The calibration 
curve was linear over the concentration range of 0.3 to 25.0 µg/mL with coefficient correlation 
of 0.9991. This method was successfully applied for therapeutic drug monitoring. 
Keywords: moxifloxacin, protein precipitation, trichloroacetic acid, HPLC method, human 
plasma. 
Classification numbers: 3.2.1. 
1. INTRODUCTION 
Moxifloxacin (1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS, 7aS) octahydro-6H-
pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4 dihydroquinoline-3-carboxylic acid (Fig. 1)) [1] is a 
fourth-generation of flouroquinolone antibacterial agent. It possesses bacteriostatic activity 
against Gram-positive and Gram-negative bacteria [2, 3]. Since having an azabicyclo-
substitution at C-7, its activity against Gram-positive bacterial as well as atypical pathogens is 
improved. It is available for oral and parenteral administration which is specially used for 
patients with respiratory or skin infection [3]. 
 
 




Figure 1. Molecular structure of moxifloxacin. 
A variety of methods on high-performance liquid chromatography (HPLC) for measuring 
moxifloxacin concentration in plasma have been reported. HPLC with fluorescence detector was 
applied in several studies [4-7]. On the other side, HPLC with UV detector was employed for 
applications in routine therapeutic drug monitoring or clinical pharmacokinetic studies of 
moxifloxacin. Most reported HPLC-UV methods involve a sample pretreatment step in which 
methanol [8], acetonitrile [9, 10] or dichloromethane [11] was used as precipitating solvent. 
Alternatively, in this paper, we report a simple HPLC-UV method for determination of 
moxifloxacin in plasma using trichloroacetic acid within deproteinization step. Precipitation can 
be achieved by varying the pH of the medium. At low pH's, proteins have a net positive charge 
because the amide gains an extra proton. At high pH's, they have a net negative charge due to the 
carboxyl on the protein backbone losing its proton. At their pI value, a protein has no net charge. 
This leads to reduced solubility because the protein is unable to interact with the medium and 
will then fall out of solution. 
2. MATERIALS AND METHODS 
2.1. Materials 
2.1.1. Chemicals and reagents 
Moxifloxacin hydrochloride standard (MOXI), yellow powder, was obtained from National 
Institute of Drug Quality Control with stated purity of 94.36 %. All solvents used were HPLC 
grade (Merck, Germany). Potassium phosphate and phosphoric acid were purity grade products 
from Merck. The used water is deionized. Other chemicals were at least of analytical grade and 
used as received. 
2.1.2. Chromatographic system  
Chromatographic analysis was performed on HPLC system (Shimadzu, Japan) with a 
PDA detector and using a MRC-ODS C18 column, 250 × 4.5 mm, 5 μm. The chromatographic 
conditions were achieved in this study according to the Liqin Zhu’s method [10]. The mobile 
phase was a mixing of 20 mM phosphate buffer (pH 4.0 adjusted by phosphoric acid) and 
acetonitrile with a ratio 30:70 (v/v), delivered at 0.8 mL/min rate. The detection was observed at 
295 nm. The column was maintained at ambient temperature with an injection volume of 20 µL. 
2.2. Methods 
2.2.1. Standard preparation 
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Standard stock solution of moxifloxacin was prepared by direct weighing of standard 
substance with subsequent dissolution in deionized water. The concentration of the standard 
stock solution was 500 µg/mL. Working standard solution of MOXI was prepared by 
withdrawing an aliquot portion of the stock solution and diluting appropriately with methanol to 
get the concentration of 10 µg/mL. The solution was filtered through a 0.45 µm nylon filter and 
degassed by ultrasonic agitation before analysis. 
2.2.2. Sample preparation  
Blank plasma samples were collected from healthy volunteers, who do not use 
moxifloxacin. 
The spiked sample was prepared by taking a known volume of moxifloxacin stock solution 
and evaporating the solvent to collect the residue (temperature 40 °C, N2 gas). The residue was 
diluted in blank plasma and vortex mixed for 2 minutes to get a spiked sample with known 
moxifloxacin concentration. 
2.2.3. Optimization of sample pretreatment 
For the analysis of biological samples, protein precipitation is the most common sample 
preparation procedure, which is the simplest approach that removes the majority of the protein 
from the sample. In our method development, trichloroacetic acid (TCA) was used as an acidic 
reagent for deproteinization. To achieve good extraction efﬁciency and protect the HPLC 
column, the human plasma pretreatment was optimized with respect to parameters including 
TCA/plasma ratio; concentration of TCA; vortex time; centrifugation time and rate. Peak area 
response was counted as changing one single variable. Optimal pretreatment procedure was 














Scheme 1. Optimal pretreatment procedure. 
2.2.4. Calibration curve in plasma matrix 
Human plasma (1 mL) 
TCA (trichloroacetic acid) 
20 % (1 mL) 
Vortex (120 s) 
Centrifuges (2000 rpm) 
in 15 minutes 
Filter supernatant 
(0.45 µm membrane) 
Inject to HPLC 
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Aliquot portions of standard working solution were added to 0.50 mL of blank plasma. 
The final moxifloxacin concentration was in a range of 0.3 - 25.0 µg/mL (10 solutions). These 
solutions were further treated to the same procedure as optimized conditions in section 2.2.3. 
2.2.5. Linearity 
The linearity of the standard curves was assessed with the intercept, slope and correlation 
coefﬁcient (R2) and their variations in the range of 0.3 - 25.0 µg/ml. The calibration samples of 
moxiﬂoxacin (0.3, 0.5, 1.0, 2.0, 4.0, 8.0, 10.0, 14.0, 18.0, 25.0 µg/mL) were prepared by 
separately spiking of prepared working standard solution of moxiﬂoxacin into 0.5 mL of blank 
plasma. The standard calibration curve for moxiﬂoxacin was constructed by least square linear 
regression using peak areas. 
2.2.6. Limit of detection and limit of quantification 
The limit of detection (LOD) and limit of quantification (LOQ) were determined by 
gradually adding moxifloxacin to blank plasma sample. LOD was obtained at the concentration 
in which height of peak signal to noise (S/N) equals to 3. LOQ was accepted as LOQ = 3.3  LOD. 
2.2.7. Precision 
Precision of analytical method was expressed as SD (Eq. 1) and %RSD (Eq. 2) of series of 
replicate measurements. 
2( )
                       (1)     
1















where: Sᵢ is the ith recovery efficiency; Stb is the average recovery of n analyses; n is the number 
of repetitions. 
2.2.8. Recovery 
Recovery (H) was calculated through the equation 3: 
% H = Ctt/Clt 100     (3) 
where Ctt is actual concentration of moxifloxacin obtained after analysis while Clt denotes added 
amount of moxifloxacin.  
3. RESULTS AND DISCUSSION 
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To evaluate the specificity of moxifloxacin determination in plasma, we performed two 
analysis for comparison: (a) blank plasma sample; (b) spiked sample with moxifloxacin of 3.0 
µg/mL. The obtained chromatograms were shown in Figure 2. Under the optimized 
chromatographic conditions and sample processing procedure, the retention time of 
moxiﬂoxacin was approximately 7.4 min. The chromatograms showed a clear and excellent 
separation between moxiﬂoxacin and endogenous interferences from plasma. No interfering 
peaks were observed at the retention time of moxiﬂoxacin. 
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Figure 2. Chromatograms of (a) blank plasma sample and (b) spiked sample with moxifloxacin of 3.0 µg/mL 
3.1.2. Linearity and regression analysis  
The calibration line for human plasma analysis was evaluated. The linearity is in the range 
of 0.03-25 µg/mL with the regression coefficient (R²) is of 0.9991. 
 
Figure 3. Calibration curve for determination of moxifloxacin in plasma. 
3.1.3. LOD and LOQ 
By gradually increasing amount of moxifloxacin in human plasma sample, the determined 
LOD and LOQ values were 0.15 and 0.50 µg/mL, respectively (Table 1). There are also lower 
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this level is satisfactory for effective determination of the concentration of the drug because 
reported the mean trough concentration was 0.59 μg/mL [12]. 




Y = (93241 ± 1834.2) X  




LOD (µg/mL) 0.15 
LOQ (µg/mL) 0.50 
Y = peak area, X = concentration of MOXI.  
3.1.4. Accuracy and precision 
The mean peak concentration of moxifloxacin in human plasma was 4.81  1.03 μg/mL as 
previously reported by Ioannis Kioumis et al. [12] In our study, precision and accuracy were 
evaluated using blank plasma spiked with three different concentration levels of moxifloxacin: 
low (1.0 µg/mL), medium (5.0 µg/mL) and high (10.0 µg/mL). Each concentration level was 
analyzed repeatedly five times. 
Table 2. Precision and accuracy evaluation (n = 5). 
Actual conc. 
(µg/mL) 






1.0 0.89  0.09 89.20 10.22 
5.0 4.27  0.10 85.39 2.34 
10.0 9.73  0.11 97.32 1.18 
The results (Table 2) show that the RSD is higher at lower concentration of MOXI. 
However, all RSD-values are smaller than 11 %, which is acceptable with the AOAC [13] 
requirement. On the other hand, mean value of the method recovery at three concentration levels 
ranged from 89.20 % to 97.32 %. According to AOAC, the analytical method for an analyte 
concentration between 1 - 10 ppm, its recovery should be within 80 - 110 %. Hence, it can be 
concluded that the proposed method has both high accuracy and precision and meets the 
requirement for analysis. 
3.2. Application 
The developed procedure was applied to determine moxifloxacin in plasma of patients who 
was infused Avelox drug with dose of 450 mg / 250 ml. These samples were collected from 
patients after 1-3 h infusing at Blood Bank of Vietnam 108-Military Hospital. 
In the previous study, the concentration-time profiles of moxiflocaxin in plasma were 
demonstrated and the mean peak concentration was 4.81 μg/mL at 1 h after infusion 400 mg. 
Furthermore, Jian Lu et al. [11] found that peak concentrations ranged from 2.60 to 3.79 g/ml 
were able to be reached within 1–3 h (mean 1.75 h) after oral dose 400 mg. The analytical 
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results for individual patients in this study were shown in Table 3. Although the weight, age, 
healthy, liver function and renal function were the important factors which caused the changes of 
moxifloxacin concentration in human plasma, these results were consistent with the previous 
studies. It is suggested that the proposed method could be applied not only for therapeutic drug 
monitoring but also for pharmacokinetic studies. 
Table 3. Analysis of moxifloxacin by proposed method.  






1 Tran Van A 1 1.52±0.05 
2 Nguyen Van B 2 2.61±0.20 
3 Cao Thi C 3 2.07±0.14 
4. CONCLUSIONS 
An HPLC-UV method for the determination of moxifloxacin in human plasma sample was 
developed and validated. The proposed method involves the following advantages: simple and 
effective sample preparation, precise and accurate assay for moxifloxacin analysis. The 
sensitivity and simplicity of the method makes it suitable for routine therapeutic drug monitoring 
or clinical pharmacokinetic studies of moxifloxacin.  
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